Get the Stockscreener App
8.02
2.30%
0.18
After Hours:
8.03
0.010
+0.12%
Gyre Therapeutics Inc stock is traded at $8.02, with a volume of 62,401.
It is up +2.30% in the last 24 hours and up +6.15% over the past month.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.84
Open:
$7.88
24h Volume:
62,401
Relative Volume:
0.66
Market Cap:
$732.34M
Revenue:
$116.59M
Net Income/Loss:
$9.88M
P/E Ratio:
356.44
EPS:
0.0225
Net Cash Flow:
$-2.40M
1W Performance:
+13.12%
1M Performance:
+6.15%
6M Performance:
-9.58%
1Y Performance:
-4.52%
1-Day Range:
$7.85
$8.05
1-Week Range:
$7.03
$8.05
52-Week Range:
$6.57
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 567-7770
Address
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.02 | 715.90M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Growth Recap: Is Gyre Therapeutics Incs ROE strong enoughDip Buying & High Conviction Trade Alerts - baoquankhu1.vn
GYRE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dow Update: Does Gyre Therapeutics Inc offer margin of safetyMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Rate Hike: Is Gyre Therapeutics Inc stock showing strong momentumWeekly Gains Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
GYRE PE Ratio & Valuation, Is GYRE Overvalued - Intellectia AI
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Growth Value: How do insiders feel about Gyre Therapeutics IncPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Portfolio Shifts: How do insiders feel about Gyre Therapeutics Inc2026 Major Catalysts & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Rally Mode: Is Gyre Therapeutics Inc a turnaround story2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Will Gyre Therapeutics Inc stock hit new highs in YEAR2026 Spike Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis - Minichart
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat
Gyre Therapeutics Files NDA in China for F351 - TipRanks
Gyre Therapeutics (GYRE) submits China NDA for Hydronidone in CHB liver fibrosis - Stock Titan
EV Market: What are analysts price targets for Gyre Therapeutics Inc2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat
China grants priority review to Gyre’s liver fibrosis drug By Investing.com - Investing.com India
China grants priority review to Gyre’s liver fibrosis drug - Investing.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget
Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics Announces China’s NMPA Grants Priority - GlobeNewswire
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - theglobeandmail.com
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat
Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView
Gyre Therapeutics (NASDAQ: GYRE) grows China fibrosis base, eyes Hydronidone NDAs - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap DownShould You Sell? - MarketBeat
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 27 '25 |
Sale |
10.28 |
2,000 |
20,560 |
2,806,642 |
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):